This trial is active, not recruiting.

Condition atrial fibrillation
Sponsor The Cleveland Clinic
Start date August 2005
End date June 2013
Trial size 1300 participants
Trial identifier NCT00599118, 8271


The purpose of this study is to establish a genebank repository of blood samples and data to generate information about the hereditary (genetic) basis of atrial fibrillation.

United States No locations recruiting
Other countries No locations recruiting

Study Design

Observational model case control
Time perspective prospective
Atrial fibrillation
Control subjects with no atrial fibrillation

Primary Outcomes

Atrial fibrillation
time frame: 4 years

Secondary Outcomes

time frame: 4 years

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria for Atrial Fibrillation group: - Male or female at least 18 years old - Subjects with a history of or current Atrial Fibrillation - Subjects able to give informed consent Inclusion Criteria for Controls: - Male or female at least 18 years old - Subjects with no history of Atrial Fibrillation - Subjects able to give informed consent

Additional Information

Official title Identification of Genetic, Biochemical and Hormonal Factors Contributing to Atrial Fibrillation
Principal investigator Mina K Chung, MD
Description Blood samples and data will be collected from subjects with atrial fibrillation and normal controls. The primary aim of future research using these samples is to identify mechanisms and pathogenesis of atrial fibrillation. Through this information, we hope to identify targets for new therapies and improve knowledge and understanding of atrial fibrillation. Identification of disease genes could improve strategies that prevent progression of atrial fibrillation to more persistent disease.
Trial information was received from ClinicalTrials.gov and was last updated in June 2010.
Information provided to ClinicalTrials.gov by The Cleveland Clinic.